Overview

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Bupropion